Portfolio at a glance
Securities as at March 31, 2021
|
Company |
|
Number of securities |
|
Change since 31.12.2020 |
|
Local currency |
|
Share price |
|
Market value in CHF mn |
|
In % of securities |
|
In % of shareholders' equity |
|
In % of company |
|
Ionis Pharmaceuticals |
|
8 166 962 |
|
(53 038) |
|
USD |
|
44.96 |
|
346.5 |
|
8.1% |
|
8.8% |
|
5.8% |
|
Moderna |
|
2 700 000 |
|
(154 963) |
|
USD |
|
130.95 |
|
333.6 |
|
7.8% |
|
8.5% |
|
0.7% |
|
Neurocrine Biosciences |
|
2 915 400 |
|
(119 600) |
|
USD |
|
97.25 |
|
267.5 |
|
6.3% |
|
6.8% |
|
3.1% |
|
Argenx SE |
|
930 538 |
|
9 206 |
|
USD |
|
275.39 |
|
241.8 |
|
5.7% |
|
6.2% |
|
1.8% |
|
Incyte |
|
2 897 000 |
|
(3 000) |
|
USD |
|
81.27 |
|
222.2 |
|
5.2% |
|
5.7% |
|
1.3% |
|
Agios Pharmaceuticals |
|
4 494 992 |
|
336 090 |
|
USD |
|
51.64 |
|
219.0 |
|
5.1% |
|
5.6% |
|
6.5% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alexion Pharmaceuticals |
|
1 294 428 |
|
– |
|
USD |
|
152.91 |
|
186.8 |
|
4.4% |
|
4.8% |
|
0.6% |
|
Vertex Pharmaceuticals |
|
900 000 |
|
– |
|
USD |
|
214.89 |
|
182.5 |
|
4.3% |
|
4.7% |
|
0.3% |
|
Fate Therapeutics |
|
2 161 336 |
|
131 336 |
|
USD |
|
82.45 |
|
168.2 |
|
3.9% |
|
4.3% |
|
2.3% |
|
Macrogenics |
|
5 070 564 |
|
255 000 |
|
USD |
|
31.85 |
|
152.4 |
|
3.6% |
|
3.9% |
|
9.0% |
|
Alnylam Pharmaceuticals |
|
1 130 000 |
|
(25 000) |
|
USD |
|
141.19 |
|
150.5 |
|
3.5% |
|
3.8% |
|
1.0% |
|
Radius Health |
|
7 455 714 |
|
– |
|
USD |
|
20.86 |
|
146.8 |
|
3.4% |
|
3.7% |
|
15.9% |
|
Biogen |
|
537 000 |
|
– |
|
USD |
|
279.75 |
|
141.8 |
|
3.3% |
|
3.6% |
|
0.4% |
|
Arvinas |
|
2 056 903 |
|
(120 000) |
|
USD |
|
66.10 |
|
128.3 |
|
3.0% |
|
3.3% |
|
4.2% |
|
Sage Therapeutics |
|
1 775 104 |
|
235 000 |
|
USD |
|
74.85 |
|
125.4 |
|
2.9% |
|
3.2% |
|
3.0% |
|
Halozyme Therapeutics |
|
2 936 966 |
|
(1 033 034) |
|
USD |
|
41.69 |
|
115.5 |
|
2.7% |
|
2.9% |
|
2.0% |
|
Intra-Cellular Therapies |
|
3 538 419 |
|
– |
|
USD |
|
33.93 |
|
113.3 |
|
2.6% |
|
2.9% |
|
4.4% |
|
Crispr Therapeutics |
|
969 584 |
|
68 700 |
|
USD |
|
121.85 |
|
111.5 |
|
2.6% |
|
2.8% |
|
1.3% |
|
Esperion Therapeutics |
|
3 947 964 |
|
– |
|
USD |
|
28.05 |
|
104.5 |
|
2.4% |
|
2.7% |
|
14.1% |
|
Scholar Rock Holding |
|
2 100 125 |
|
(155 526) |
|
USD |
|
50.66 |
|
100.4 |
|
2.3% |
|
2.6% |
|
6.1% |
|
Myovant Sciences |
|
5 147 039 |
|
390 000 |
|
USD |
|
20.58 |
|
100.0 |
|
2.3% |
|
2.6% |
|
5.7% |
|
Molecular Templates |
|
8 116 105 |
|
1 735 774 |
|
USD |
|
12.62 |
|
96.6 |
|
2.3% |
|
2.5% |
|
14.5% |
|
Generation Bio Co. |
|
2 393 180 |
|
60 000 |
|
USD |
|
28.46 |
|
64.3 |
|
1.5% |
|
1.6% |
|
4.2% |
|
Relay Therapeutics |
|
1 931 344 |
|
521 987 |
|
USD |
|
34.57 |
|
63.0 |
|
1.5% |
|
1.6% |
|
2.1% |
|
Exelixis |
|
2 835 000 |
|
– |
|
USD |
|
22.59 |
|
60.4 |
|
1.4% |
|
1.5% |
|
0.9% |
|
Black Diamond Therapeutics |
|
2 230 000 |
|
840 000 |
|
USD |
|
24.26 |
|
51.0 |
|
1.2% |
|
1.3% |
|
6.2% |
|
Essa Pharma |
|
1 825 814 |
|
1 825 814 |
|
USD |
|
29.05 |
|
50.0 |
|
1.2% |
|
1.3% |
|
4.7% |
|
Nektar Therapeutics |
|
2 620 676 |
|
– |
|
USD |
|
20.00 |
|
49.5 |
|
1.2% |
|
1.3% |
|
1.4% |
|
Revolution Medicines |
|
1 007 770 |
|
1 007 770 |
|
USD |
|
45.88 |
|
43.6 |
|
1.0% |
|
1.1% |
|
1.4% |
|
Beam Therapeutics |
|
566 821 |
|
170 000 |
|
USD |
|
80.04 |
|
42.8 |
|
1.0% |
|
1.1% |
|
0.9% |
|
Mersana Therapeutics |
|
2 760 000 |
|
875 000 |
|
USD |
|
16.18 |
|
42.1 |
|
1.0% |
|
1.1% |
|
4.0% |
|
Kezar Life Sciences |
|
4 533 148 |
|
– |
|
USD |
|
5.96 |
|
25.5 |
|
0.6% |
|
0.7% |
|
9.4% |
|
Homology Medicines |
|
1 737 122 |
|
– |
|
USD |
|
9.41 |
|
15.4 |
|
0.4% |
|
0.4% |
|
3.4% |
|
Wave Life Sciences |
|
2 602 858 |
|
– |
|
USD |
|
5.61 |
|
13.8 |
|
0.3% |
|
0.4% |
|
5.3% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alder Biopharmaceuticals – Contingent Value Right |
|
2 766 008 |
|
– |
|
USD |
|
0.88 |
|
2.3 |
|
0.1% |
|
0.1% |
|
|
|
Bristol-Myers Squibb – Contingent Value Right |
|
– |
|
(800 000) |
|
USD |
|
0.00 |
|
0.0 |
|
0.0% |
|
0.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total securities |
|
|
|
|
|
|
|
|
|
4 278.8 |
|
100.0% |
|
109.2% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
|
4.1 |
|
|
|
0.1% |
|
|
|
Other payables |
|
|
|
|
|
|
|
|
|
(364.4) |
|
|
|
(9.3%) |
|
|
|
Net asset value |
|
|
|
|
|
|
|
|
|
3 918.5 |
|
|
|
100.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BB Biotech registered shares 1) |
|
– |
|
(114 662) |
|
|
|
|
|
|
|
|
|
|
|
|
1 Correspond to the total of all own shares held including the second trading line
Exchange rate as at 31.03.2021: USD/CHF: 0.9436